Korsana Biosciences, Inc. KRSA
31.43 USD -0.41 (-1.28%)
Nov 12, 2026, 2:11 PM EST
30.54 Day range 31.89
7.19 52-week range 59.36
- YTD
- +253.57%
- 1 year
- +216.23%
News
benzinga.com Korsana Biosciences Q3 EPS $(3.19) Misses $(0.85) Estimate Korsana Biosciences (NASDAQ:KRSA) reported quarterly losses of $(3.19) per share which missed the analyst consensus estimate of $(0.85) by 275.29 percent. This is a 91.92 percent increase over losses…
globenewswire.com Korsana Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in…
benzinga.com Wedbush Initiates Coverage On Korsana Biosciences with Outperform Rating, Announces Price Target of $44 Wedbush analyst Laura Chico initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Outperform rating and announces Price Target of $44.
benzinga.com Guggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70 Guggenheim analyst Yatin Suneja initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $70.- benzinga.com Stifel Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $43 Stifel analyst Paul Matteis initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $43.
- benzinga.com UBS Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $55 UBS analyst Michael Yee initiates coverage on Korsana Biosciences (NASDAQ:KRSA) with a Buy rating and announces Price Target of $55.